TEST:

RNAscope™ ISH Probe High Risk HPV

This chapter is a revised version of the first Edition which aims to describe a method used to evaluate gene expression and microRNAs (miRNAs) in bone cells or bone tissue using Reverse transcription and quantitative Polymerase Chain Reaction (RT-qPCR), and methods to assess chromogenic in situ hybridization (CISH) on Formalin Fixed Paraffin Embedded (FFPE) mouse bone tissue to detect both DNA and mRNA transcripts using the double digoxigenin (DIG) locked nucleic acid (LNA™) probes or using RNAscope technology.

The in situ expression of E6/E7 mRNA for eighteen HRHPV genotypes shows a significant increased expression from normal cervix and CIN I to CIN III with confirmed transforming HPV-18 infection. These findings suggest that detecting HR-HPV E6/E7 mRNA in situ expression by CISH staining in CIN could help to grade these lesions more accurately. The expression of E6/E7 HPV mRNA in cervical carcinogenesis is an aspect of the progression of this neoplasm that should continue to be studied.

In situ evaluation of the RBP1 gene mRNA shows differential expression in HSIL compared to LSIL and healthy cervical tissue, confirming the finding found in the previously performed gene profile. The differential expression of TMEM45A between normal cervix and HSIL favours a possible role of this gene in the carcinogenesis of well-differentiated epithelial lesions. Additional studies are being performed to detect the expression of these genes at the protein level and determine if there is a correlation with these findings.

"Bio-Techne Corporation...announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland."

"Bio-Techne Corporation...announced that it has taken legal action in the Unified Patent Court in Europe to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc."

"Bio-Techne Corporation...announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's spatial biology division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope™ ISH technology."

Our findings provide additional evidence that the CSF1/CSF1R pathway is involved in the pathogenesis of XGET/KPGCT. These findings suggest a possible role for CSF1R inhibition in the treatment of unresectable or metastatic XGET/KPGCT.

IGK/L double-negative cells were detected in 1 PMBCL, 2 MGZL, and all classical HL, while monotypic IgLC expression appeared to be a hallmark in nodular lymphocyte-predominant HL. IgLC-RNAsc demonstrates to be a powerful tool in B-cell lymphoma diagnosis, above all in challenging cases with limited tumor cell content, ensuring in situ investigations on mechanisms of Ig regulation across lymphoma entities.

"Bio-Techne...announced that the company will end their collaboration with Akoya Biosciences to co-develop an automated RNAscope™ workflow for use with the PhenoCycler®-Fusion System...Bio-Techne will continue to support its customers utilizing RNAscope assays in conjunction with Opal™ reagents and PhenoImager™ HT systems purchased from Akoya."

"Bio-Techne...announced the launch of two new RNAscope™ in situ Hybridization Probes Kappa and Lambda as analyte specific reagents (ASRs) for the detection of immunoglobulin kappa and lambda light chains mRNA in B-cells...RNAscope ISH Probes Kappa and Lambda are designed to detect immunoglobulin kappa and lambda light chains mRNA. RNAscope probes are visualized with the highly sensitive RNAscope ISH detection reagents, which are compatible with FFPE tissue."

"Bio-Techne...and Lunaphore...announced a strategic partnership to develop the first fully automated spatial multiomics workflow with same-slide hyperplex detection of protein and RNA biomarkers. Designed to provide ultimate flexibility in panel design, the solution will allow researchers to easily combine well-characterized antibodies with gold-standard RNAscope™ in situ hybridization probes to illuminate changes in cell phenotypes and functional states across a wide range of diseases."

"Bio-Techne Corporation...announced it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 14-19 in Orlando, Florida."